Literature DB >> 28090522

Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.

Chul Kim1, Giuseppe Giaccone2.   

Abstract

Entities:  

Year:  2016        PMID: 28090522      PMCID: PMC5220042          DOI: 10.21037/atm.2016.11.48

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  22 in total

1.  EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.

Authors:  Lynette M Sholl; Yun Xiao; Victoria Joshi; Beow Y Yeap; Leigh-Anne Cioffredi; David M Jackman; Charles Lee; Pasi A Jänne; Neal I Lindeman
Journal:  Am J Clin Pathol       Date:  2010-06       Impact factor: 2.493

2.  Adaptive Randomization of Neratinib in Early Breast Cancer.

Authors:  John W Park; Minetta C Liu; Douglas Yee; Christina Yau; Laura J van 't Veer; W Fraser Symmans; Melissa Paoloni; Jane Perlmutter; Nola M Hylton; Michael Hogarth; Angela DeMichele; Meredith B Buxton; A Jo Chien; Anne M Wallace; Judy C Boughey; Tufia C Haddad; Stephen Y Chui; Kathleen A Kemmer; Henry G Kaplan; Claudine Isaacs; Rita Nanda; Debasish Tripathy; Kathy S Albain; Kirsten K Edmiston; Anthony D Elias; Donald W Northfelt; Lajos Pusztai; Stacy L Moulder; Julie E Lang; Rebecca K Viscusi; David M Euhus; Barbara B Haley; Qamar J Khan; William C Wood; Michelle Melisko; Richard Schwab; Teresa Helsten; Julia Lyandres; Sarah E Davis; Gillian L Hirst; Ashish Sanil; Laura J Esserman; Donald A Berry
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

3.  Outcome--adaptive randomization: is it useful?

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

Review 4.  Refining the treatment of NSCLC according to histological and molecular subtypes.

Authors:  Anish Thomas; Stephen V Liu; Deepa S Subramaniam; Giuseppe Giaccone
Journal:  Nat Rev Clin Oncol       Date:  2015-05-12       Impact factor: 66.675

5.  Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.

Authors:  Edward S Kim; Merrill S Kies; Frank V Fossella; Bonnie S Glisson; Sara Zaknoen; Paul Statkevich; Reginald F Munden; Carmen Summey; Katherine M W Pisters; Vali Papadimitrakopoulou; Mourad Tighiouart; Andre Rogatko; Fadlo R Khuri
Journal:  Cancer       Date:  2005-08-01       Impact factor: 6.860

6.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Authors:  Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò
Journal:  Lancet Oncol       Date:  2012-11-28       Impact factor: 41.316

7.  Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

Authors:  C A Carter; A Rajan; C Keen; E Szabo; S Khozin; A Thomas; C Brzezniak; U Guha; L A Doyle; S M Steinberg; L Xi; M Raffeld; Y Tomita; M J Lee; S Lee; J B Trepel; K L Reckamp; S Koehler; B Gitlitz; R Salgia; D Gandara; E Vokes; G Giaccone
Journal:  Ann Oncol       Date:  2016-01-22       Impact factor: 32.976

8.  The cross-validated adaptive signature design.

Authors:  Boris Freidlin; Wenyu Jiang; Richard Simon
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

9.  The BATTLE trial: personalizing therapy for lung cancer.

Authors:  Edward S Kim; Roy S Herbst; Ignacio I Wistuba; J Jack Lee; George R Blumenschein; Anne Tsao; David J Stewart; Marshall E Hicks; Jeremy Erasmus; Sanjay Gupta; Christine M Alden; Suyu Liu; Ximing Tang; Fadlo R Khuri; Hai T Tran; Bruce E Johnson; John V Heymach; Li Mao; Frank Fossella; Merrill S Kies; Vassiliki Papadimitrakopoulou; Suzanne E Davis; Scott M Lippman; Waun K Hong
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

10.  A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.

Authors:  James M S Wason; Lorenzo Trippa
Journal:  Stat Med       Date:  2014-01-14       Impact factor: 2.373

View more
  3 in total

1.  Tumor molecular profiling of NSCLC patients using next generation sequencing.

Authors:  Nikolaos Tsoulos; Eirini Papadopoulou; Vasiliki Metaxa-Mariatou; Georgios Tsaousis; Chrisoula Efstathiadou; Georgia Tounta; Aikaterini Scapeti; Eugenia Bourkoula; Pavlos Zarogoulidis; George Pentheroudakis; Stylianos Kakolyris; Ioannis Boukovinas; Pavlos Papakotoulas; Elias Athanasiadis; Theofanis Floros; Anna Koumarianou; Vasileios Barbounis; Anca Dinischiotu; George Nasioulas
Journal:  Oncol Rep       Date:  2017-10-23       Impact factor: 3.906

Review 2.  Ethical considerations of neuro-oncology trial design in the era of precision medicine.

Authors:  Saksham Gupta; Timothy R Smith; Marike L Broekman
Journal:  J Neurooncol       Date:  2017-05-29       Impact factor: 4.130

Review 3.  Precision Oncology-The Quest for Evidence.

Authors:  Theodoros G Soldatos; Sajo Kaduthanam; David B Jackson
Journal:  J Pers Med       Date:  2019-09-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.